https://www.zacks.com/stock/news/2199442/vertex-vrtx-crispr-get-positive-chmp-opinion-for-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199442
Dec 18, 2023 - Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
zc:7240804203094881107
0
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
zc:-1921715234579021585
0
https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198026
Dec 14, 2023 - bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
zc:-8362632759954787601
0
https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197830
Dec 14, 2023 - Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
zc:-8729598621944536751
0
https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/?source=iedfolrf0000001
Dec 13, 2023 - The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
0
fool:7558414813686740199
0
https://www.zacks.com/stock/news/2196355/blue-crsp-vrtx-down-despite-fda-nod-to-scd-therapies?cid=CS-ZC-FT-analyst_blog|industry_focus-2196355
Dec 11, 2023 - The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
zc:6097787946806305961
0
https://www.zacks.com/stock/news/2196255/bluebird-blue-down-despite-fda-nod-to-gene-therapy-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196255
Dec 11, 2023 - bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
zc:-7716201647974566946
0
https://www.zacks.com/stock/news/2196180/crispr-crsp-vertex-fall-despite-fda-nod-to-scd-drug-casgevy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196180
Dec 11, 2023 - CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.
zc:-1699726404515125758
0
https://www.fool.com/investing/2023/12/06/is-this-setback-or-step-forward-for-crispr/?source=iedfolrf0000001
Dec 06, 2023 - It's important to look at the news through a long-term lens.
0
fool:-6814820600454516289
0
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
zc:7993331517159655985
0